Benjamin Lemon

MS3 at Mercer University School of Medicine | UGA 2023 | Aspiring Urologist | Director of Communications for @UroResidency

[Benjamin J. Davies MD, MBA @daviesbj]

My first paper with Alex and it's a doozy (also jay, canes, QDT)

$ISRG and others stealing our IP. We have issues

[Dr. Edward Oates @traumaticum]

ohhh hell yeahhh !!

In final prototype testing phase on https://t.co/1WvAMhHtn0

Not for public use yet, but im pretty sure you'll find this as cool as I do!

post a random sketch and ill test run it, and we'll see how it goes !!

#orthotwitter
#medtwitter

[Scott Eggener @uroegg]

First ever locally injectable immunoactive agent with proven DFS benefit in localized prostate cancer.

Tandem randomized Phase II in surveillance forthcoming.

Origin: Baylor basic science lab (support research!)

https://t.co/gGOjo9eMa5

[Elie Kaplan-Marans, MD @Doctor__KM]

Future legend and Men's Health expert Dr. Nick Deebel @ndeebel_uroMD tells us:

"What do you do for a living?"

@SMSNA_ORG @NYSAUA @AmerUrological

[Eric Topol @EricTopol]

Another major advance vs cancer! @ASCO #ASCO26
Personalized neoantigen mRNA vaccine 5 year follow-up vs metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda)
https://t.co/NadITTYIT2

[𝙳𝚊𝚟𝚒𝚍 𝙲𝚊𝚗𝚎𝚜 @CanesDavid]

Thoughtful review of the PROTEUS trial by @DrSpratticus
First, real credit to the investigators. Pulling off a phase 3 perioperative RCT in localized prostate cancer is a massive undertaking, and easy to forget when you're critiquing from the armchair (mea culpa, I don't run trials like this).
That said, Daniel is essentially pointing out (I think 🤪) that PSMA-PET catches BCR so early that "metastasis-free survival" is really just biochemical recurrence in disguise, and EFS is a lousy surrogate for OS (see his tweetorial for the reasons).
The part that confuses me most: this isn't compared to standard of care. We don't give ADT with prostatectomy. So what are we supposed to do with this information?

https://t.co/JbdeXwbnLj

@DrSpratticus @adamkibel_uro @uretericbud @daviesbj

[Matt Cooperberg @dr_coops]

Hot off the @NEJM press: PROTEUS trial of neoadj ADT/apalutamide with RP from Mary Ellen Taplin et al. First major positive results in this space. And thought provoking editorial from @EAntonarakis. Do you agree??

Plenary presentation at #ASCO26 in about 10 minutes, stay tuned!

https://t.co/8mlljuP38T

https://t.co/sDc0x4h8lK

[Fernando GomezSancha @fgomsan]

Hoy, el NEJM publica el ensayo PROTEUS: la apalutamida perioperatoria mejora la respuesta patológica y la supervivencia libre de metástasis en el cáncer de próstata de alto riesgo. ¡Un artículo historico!

Enhorabuena a mi compañero, el Dr. @alvarojuarezs (Urólogo de ICUA), único firmante español del estudio.

[Fernando GomezSancha @fgomsan]

Prostate volume doesn't reliably predict obstruction — and we've known it for decades. A new open-access review in PCAN introduces a new concept: periurethral and transition-zone fibrosis is an under-recognised, untreated driver of LUTS/BPH.
The case for antifibrotics: pirfenidone, losartan, PDE5-i, even halofuginone. https://t.co/vIw1BF5CJs

[Benjamin Lemon @LemonBenjamin01]

@ciirarref Civil War surgeon maxing

[JAMA Cardiology @JAMACardio]

Premature menopause (age <40 years) was associated with a 40% higher lifetime risk of #CoronaryHeartDisease in both Black and White women, supporting its use as a risk-enhancing factor in preventive care. https://t.co/CEoV8jFMU9

[Avi Roy @agingroy]

Stop a statin and your LDL cholesterol rises 30% in four days. Nobody writes a WSJ feature about it. Stop certain blood pressure medications and your BP can spike within hours. Nobody calls it a design flaw.

Levothyroxine, antidepressants, insulin, metformin, antihistamines. Chronic treatments for chronic conditions, and all of them stop working when you stop taking them. None of them generate think-pieces questioning whether patients should have started.

The AMA classified obesity as a disease in 2013. Thirteen years later, it’s still the only chronic condition where “you have to take it forever” is framed as an argument against treatment rather than a description of how medicine works.

[Avi Roy @agingroy]

Eli Lilly released retatrutide Phase 3 data yesterday. 28% weight loss in 80 weeks. The most powerful obesity drug that’s ever been tested.

And today the cancer signal drops.

12,112 patients. Seven tumor types. GLP-1 users had half the lung cancer metastasis rate (10% vs 22%). Breast cancer: 43% cut. Colon cancer five-year mortality in a separate study: 15.5% vs 37.1%.

Cancer joins a list that already includes heart disease (SELECT, 20% MACE reduction), kidney failure (FLOW, 24% slower decline), sleep apnea (SURMOUNT-OSA, FDA-approved), addiction (BMJ, 600K veterans, 18-25% reduction across substances), and liver disease (86% fat clearance).

Tumors express GLP-1 receptors. Activate them and NF-kB drops, apoptosis rises. The drug isn’t just shrinking fat. It’s talking directly to the cancer.

One drug class. Designed for blood sugar. The biology keeps finding uses the designers didn’t predict.

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

I am excited to join the @MayoClinic @MayoRadOnc team in Florida as Mayo expands its next-generation #radonc program.

@DanTrifMD @KarinaNietoMD @BradfordHoppe @albertattia7 @LauraVallow @fantinegiap et al

https://t.co/Hud6LoBI8K

[Benjamin Lemon @LemonBenjamin01]

@Mrwailee So good you’ve gained an extra letter

[Shankar Siva @_ShankarSiva]

#ESTRO26 - 📣 FASTRACKII final results, median F/U of 5 years. Thank you patients, funders, investigators - #kidneycancer #kcsm
1) 100% Local Control: No local recurrences were observed at 36, 60, or 84 months.
2) 100% Cancer-Specific Survival
3) Grade 3 AEs remain at 10%

[Roger Khouri Jr MD @rogerkhourijr]

https://t.co/hx2EqNBReW

RE: What makes a great urology sub-internship?

[Epic @HeyEpic]

How does 5 years of data sound?

BMI and GLP-1 trends are now available on the Epic Research Data Tracker:

[MUSC Urologic Oncology Program @MUSC_UroOnc]

🚨Unexpected opening for July 2026 🚨

• 1-year fellowship with comprehensive training in SP, laparoscopic, focal therapy, multiport robotics, and open surgery
• High volumes (300+ major oncologic cases)
• Strong mentorship, outstanding team, beautiful city

Interested candidates — reach out via DM ✉️

https://t.co/D9MwndFa2j

@EMW2000 @MatveyTsivian @JayChavaliMD @JL_Drerup @SES_AUA @UroOnc @SUO_YUO @GenevaMaeP @SBoorjian @michaelabern @benvstone

[OpenEvidence @EvidenceOpen]

Until now, physicians using AI in clinic had to assemble the patient’s context themselves. Allergies, comorbidities, medications, prior procedures, copy-pasted in from the chart.

Today we’re announcing a partnership with @CedarsSinai. OpenEvidence now works directly inside Epic, drawing on the patient’s full record and interpreting the medical literature through the lens of that specific patient.

Cedars-Sinai is the first academic health system to deploy patient-aware clinical intelligence at enterprise scale. The clinician asks a complex question in natural language. The answer reflects both the best available evidence and the patient in front of them.

Patient data is never stored after the clinical session or used for any other purpose.